← USPTO Patent Grants

Polyurethane excipient

Grant US12589153B2 Kind: B2 Mar 31, 2026

Assignee

DSM IP ASSETS B.V.

Inventors

Jennifer Al-Rashid, Jacob Riffey, John Andrew Zupancich

Abstract

In an embodiment, a polyurethane comprises the residues of i. an aliphatic diisocyanate, ii. an aliphatic diol comprising a poly(ethylene oxide) moiety, iii. an aliphatic diol comprising a polycarbonate moiety, and iv. a chain extender, wherein the polyurethane has a melting temperature of 140° C. or less and has a weight average molecular weight of from 100,000 to 500,000 g/mol. In an embodiment, the polyurethane is substantially devoid of catalyst. In an embodiment, the polyurethane is formed by reactive extrusion. In an embodiment, a medical device comprises the polyurethane and a bioactive agent. The medical devices, methods, and polyurethanes may exhibit benefits in end-product biostability, drug release profile, health and safety, and processing speed or reproducibility.

CPC Classifications

A61K 47/34 A61K 9/0036 A61K 47/32 C08G 18/12 C08G 18/4018 C08G 18/44 C08G 18/4833 C08G 18/73 C08G 18/758 C08G 18/0895 C08G 18/3206

Filing Date

2024-12-17

Application No.

18984821

Claims

18